MedTrace Logo

Immunoadsorption and Immunoglobulin Substitution for Heart Failure After Myocardial Infarction

NCT00738517 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2016-05-11

No results posted yet for this study

Summary

The purpose of this study is to investigate, if immunoadsorption of autoantibodies with subsequent substitution of immunoglobulins is able to improve cardiac function of patients with heart failure after myocardial infarction and presence of cardiac autoantibodies.

Conditions

Interventions

DEVICE

Immunoadsorption / Immunoglobulin substitution

Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)

Sponsors & Collaborators

  • Fresenius Medical Care North America

    collaborator INDUSTRY

  • University Medicine Greifswald

    lead OTHER

Principal Investigators

  • Stephan B Felix, MD · University Medicine Greifswald

  • Lars R Herda, MD · University Medicine Greifswald

  • Astrid Hummel, MD · University Medicine Greifswald

  • Marcus Doerr, MD · University Medicine Greifswald

  • Daniel Beug, MD · University Medicine Greifswald

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2011-06-30
Completion
2011-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00738517 on ClinicalTrials.gov